Philips to halt CPAP sales in the U.S. as it takes $393 million provision

by | Jan 29, 2024 | Stock Market

Philips on Monday said it will halt the sales of new sleep-therapy devices in the U.S., as part of a broader settlement that led the company to take a €363 million ($393 million) provision in the final quarter of the year. Philips said it will not sell any new Continuous Positive Airway Pressure or Bilevel Positive Airway Pressure sleep therapy devices or other respiratory care devices in the U.S., until it meets the requirements of a consent decree with the U.S. Justice Department that is being finalized but will need court approval.

Philips will be able to service existing machines and sell accessories, and the restrictions will not apply outside the U.S. Analysts at UBS estimate the consent decree will lead to a roughly €400 million sales headwind. Philips said the new provision covers remediation activities, inventory write-downs and onerous contract provisions. Philips has had to recall millions of sleep therapy and respiratory machines because of the risk that the foam used in the devices breaks down and can be swallowed. More recently, the Food and Drug Administration reported the risk of overheating in newer devices. The settlement terms were released as part of its fourth-quarter financials, in which it swung to a €38 m …

Article Attribution | Read More at Article Source

[mwai_chat context=”Let’s have a discussion about this article:nnPhilips on Monday said it will halt the sales of new sleep-therapy devices in the U.S., as part of a broader settlement that led the company to take a €363 million ($393 million) provision in the final quarter of the year. Philips said it will not sell any new Continuous Positive Airway Pressure or Bilevel Positive Airway Pressure sleep therapy devices or other respiratory care devices in the U.S., until it meets the requirements of a consent decree with the U.S. Justice Department that is being finalized but will need court approval.

Philips will be able to service existing machines and sell accessories, and the restrictions will not apply outside the U.S. Analysts at UBS estimate the consent decree will lead to a roughly €400 million sales headwind. Philips said the new provision covers remediation activities, inventory write-downs and onerous contract provisions. Philips has had to recall millions of sleep therapy and respiratory machines because of the risk that the foam used in the devices breaks down and can be swallowed. More recently, the Food and Drug Administration reported the risk of overheating in newer devices. The settlement terms were released as part of its fourth-quarter financials, in which it swung to a €38 m …nnDiscussion:nn” ai_name=”RocketNews AI: ” start_sentence=”Can I tell you more about this article?” text_input_placeholder=”Type ‘Yes'”]

Share This